EV/Sales Ratio: 3.76x
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 3.76x is 69% below its 5-year average of 12.19x, near the low end of its 5-year range (3.52x–21.78x).
As of Thursday, June 25, 2026. 51.52% below its 12-month average of 7.76x.
PODD EV/Sales Ratio Chart
PODD Average EV/Sales Ratio Chart
PODD Current vs Average EV/Sales Ratio Chart
PODD EV/Sales Ratio Metrics
EV/SALES RATIO
3.76x
EV/SALES RATIO AVG TTM
7.76x
EV/SALES RATIO AVG 3Y
8.94x
EV/SALES RATIO AVG 5Y
12.19x
EV/SALES RATIO AVG 10Y
12.39x
EV/SALES RATIO AVG 15Y
10.55x
EV/SALES RATIO AVG 20Y
10.23x
CURRENT VS TTM AVG
-51.52%
CURRENT VS 3Y AVG
-57.93%
CURRENT VS 5Y AVG
-69.15%
CURRENT VS 10Y AVG
-69.65%
CURRENT VS 15Y AVG
-64.37%
CURRENT VS 20Y AVG
-63.23%
PODD Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 3.76x | 7.76x | 8.94x | 12.19x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.25x | 0.26x | 0.37x | 0.45x |
| Baxter International Inc. (BAX)vs › | $10.87B | 1.63x | 1.70x | 2.16x | 2.63x |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | 3.17x | 2.81x | 3.02x | 3.77x |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 0.99x | 0.94x | 0.94x | 0.95x |
| Revvity, Inc. (RVTY)vs › | $11.78B | 4.93x | 4.79x | 5.55x | 5.57x |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 2.76x | 2.72x | 4.03x | 5.81x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 3.25x | 3.42x | 3.66x | 4.55x |
| Oscar Health, Inc. (OSCR)vs › | $7.56B | 0.39x | 0.23x | 0.31x | 0.44x |
| Solventum Corporation (SOLV)vs › | $13.09B | 2.15x | 2.18x | 2.26x | 2.26x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Insulet Corp. (PODD)?
- The EV/Sales ratio for PODD stock is 3.76x.
- Is Insulet Corp.'s EV/Sales ratio high or low?
- The EV/Sales ratio of 3.76x is 69% below its 5-year average of 12.19x, near the low end of its 5-year range (3.52x–21.78x).
- What is the TTM average EV/Sales ratio for Insulet Corp. (PODD)?
- The TTM average EV/Sales ratio for PODD stock is 7.76x.
- What is the 3Y average EV/Sales ratio for Insulet Corp. (PODD)?
- The 3Y average EV/Sales ratio for PODD stock is 8.94x.
- What is the 5Y average EV/Sales ratio for Insulet Corp. (PODD)?
- The 5Y average EV/Sales ratio for PODD stock is 12.19x.
- What is the 10Y average EV/Sales ratio for Insulet Corp. (PODD)?
- The 10Y average EV/Sales ratio for PODD stock is 12.39x.
- What is the 15Y average EV/Sales ratio for Insulet Corp. (PODD)?
- The 15Y average EV/Sales ratio for PODD stock is 10.55x.
- What is the 20Y average EV/Sales ratio for Insulet Corp. (PODD)?
- The 20Y average EV/Sales ratio for PODD stock is 10.23x.
PODD EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-24 | 3.76x |
| 2026-06-23 | 3.64x |
| 2026-06-22 | 3.52x |
| 2026-06-18 | 3.69x |
| 2026-06-17 | 3.63x |
| 2026-06-16 | 3.74x |
| 2026-06-15 | 3.75x |
| 2026-06-12 | 3.78x |
| 2026-06-11 | 3.77x |
| 2026-06-10 | 3.81x |
| 2026-06-09 | 4.02x |
| 2026-06-08 | 3.83x |
| 2026-06-05 | 3.87x |
| 2026-06-04 | 3.70x |
| 2026-06-03 | 3.63x |
| 2026-06-02 | 3.61x |
| 2026-06-01 | 3.75x |
| 2026-05-29 | 3.67x |
| 2026-05-28 | 3.61x |
| 2026-05-27 | 3.69x |
| 2026-05-26 | 3.88x |
| 2026-05-22 | 3.91x |
| 2026-05-21 | 3.96x |
| 2026-05-20 | 3.95x |
| 2026-05-19 | 3.90x |
| 2026-05-18 | 3.85x |
| 2026-05-15 | 3.73x |
| 2026-05-14 | 3.76x |
| 2026-05-13 | 3.76x |
| 2026-05-12 | 3.99x |
| 2026-05-11 | 3.89x |
| 2026-05-08 | 3.89x |
| 2026-05-07 | 4.04x |
| 2026-05-06 | 3.82x |
| 2026-05-05 | 4.50x |
| 2026-05-04 | 4.60x |
| 2026-05-01 | 4.69x |
| 2026-04-30 | 4.62x |
| 2026-04-29 | 4.30x |
| 2026-04-28 | 4.90x |
| 2026-04-27 | 5.04x |
| 2026-04-24 | 5.07x |
| 2026-04-23 | 5.14x |
| 2026-04-22 | 5.18x |
| 2026-04-21 | 5.14x |
| 2026-04-20 | 5.37x |
| 2026-04-17 | 5.44x |
| 2026-04-16 | 5.38x |
| 2026-04-15 | 5.41x |
| 2026-04-14 | 5.38x |
| 2026-04-13 | 5.29x |
| 2026-04-10 | 5.26x |
| 2026-04-09 | 5.33x |
| 2026-04-08 | 5.43x |
| 2026-04-07 | 5.41x |
| 2026-04-06 | 5.43x |
| 2026-04-02 | 5.45x |
| 2026-04-01 | 5.53x |
| 2026-03-31 | 5.60x |
| 2026-03-30 | 5.55x |
| 2026-03-27 | 5.56x |
| 2026-03-26 | 5.81x |
| 2026-03-25 | 5.76x |
| 2026-03-24 | 6.01x |
| 2026-03-23 | 6.05x |
| 2026-03-20 | 6.05x |
| 2026-03-19 | 6.09x |
| 2026-03-18 | 6.13x |
| 2026-03-17 | 6.14x |
| 2026-03-16 | 5.99x |
| 2026-03-13 | 5.86x |
| 2026-03-12 | 6.28x |
| 2026-03-11 | 6.36x |
| 2026-03-10 | 6.34x |
| 2026-03-09 | 6.40x |
| 2026-03-06 | 6.31x |
| 2026-03-05 | 6.41x |
| 2026-03-04 | 6.46x |
| 2026-03-03 | 6.43x |
| 2026-03-02 | 6.53x |
| 2026-02-27 | 6.56x |
| 2026-02-26 | 6.69x |
| 2026-02-25 | 6.60x |
| 2026-02-24 | 6.52x |
| 2026-02-23 | 6.63x |
| 2026-02-20 | 6.44x |
| 2026-02-19 | 6.62x |
| 2026-02-18 | 6.86x |
| 2026-02-17 | 7.01x |
| 2026-02-13 | 6.91x |
| 2026-02-12 | 6.86x |
| 2026-02-11 | 7.14x |
| 2026-02-10 | 7.18x |
| 2026-02-09 | 6.99x |
| 2026-02-06 | 6.89x |
| 2026-02-05 | 6.92x |
| 2026-02-04 | 7.15x |
| 2026-02-03 | 7.15x |
| 2026-02-02 | 7.30x |
| 2026-01-30 | 7.28x |
| 2026-01-29 | 7.26x |
| 2026-01-28 | 7.34x |
| 2026-01-27 | 7.53x |
| 2026-01-26 | 7.71x |
| 2026-01-23 | 7.72x |
| 2026-01-22 | 7.95x |
| 2026-01-21 | 8.09x |
| 2026-01-20 | 8.07x |
| 2026-01-16 | 8.17x |
| 2026-01-15 | 8.14x |
| 2026-01-14 | 8.03x |
| 2026-01-13 | 7.90x |
| 2026-01-12 | 7.91x |
| 2026-01-09 | 8.21x |
| 2026-01-08 | 8.32x |
| 2026-01-07 | 8.49x |
| 2026-01-06 | 8.36x |
| 2026-01-05 | 8.05x |
| 2026-01-02 | 8.04x |
| 2025-12-31 | 8.07x |
| 2025-12-30 | 8.15x |
| 2025-12-29 | 8.16x |
| 2025-12-26 | 8.20x |
| 2025-12-24 | 8.20x |
| 2025-12-23 | 8.11x |
| 2025-12-22 | 8.28x |
| 2025-12-19 | 8.22x |
| 2025-12-18 | 8.31x |
| 2025-12-17 | 8.22x |
| 2025-12-16 | 8.20x |
| 2025-12-15 | 8.28x |
| 2025-12-12 | 8.39x |
| 2025-12-11 | 8.35x |
| 2025-12-10 | 8.38x |
| 2025-12-09 | 8.35x |
| 2025-12-08 | 8.41x |
| 2025-12-05 | 8.64x |
| 2025-12-04 | 8.96x |
| 2025-12-03 | 8.73x |
| 2025-12-02 | 8.77x |
| 2025-12-01 | 8.82x |
| 2025-11-28 | 9.28x |
| 2025-11-26 | 9.27x |
| 2025-11-25 | 9.32x |
| 2025-11-24 | 9.57x |
| 2025-11-21 | 9.39x |
| 2025-11-20 | 8.88x |
| 2025-11-19 | 9.81x |
| 2025-11-18 | 9.45x |
| 2025-11-17 | 9.30x |
| 2025-11-14 | 9.43x |
| 2025-11-13 | 9.43x |
| 2025-11-12 | 9.55x |
| 2025-11-11 | 9.25x |
| 2025-11-10 | 9.08x |
| 2025-11-07 | 9.07x |
| 2025-11-06 | 9.17x |
| 2025-11-05 | 9.59x |
| 2025-11-04 | 9.77x |
| 2025-11-03 | 9.72x |
| 2025-10-31 | 9.55x |
| 2025-10-30 | 9.52x |
| 2025-10-29 | 9.65x |
| 2025-10-28 | 9.89x |
| 2025-10-27 | 9.93x |
| 2025-10-24 | 9.79x |
| 2025-10-23 | 9.86x |
| 2025-10-22 | 10.04x |
| 2025-10-21 | 10.03x |
| 2025-10-20 | 9.97x |
| 2025-10-17 | 9.72x |
| 2025-10-16 | 9.65x |
| 2025-10-15 | 9.53x |
| 2025-10-14 | 9.71x |
| 2025-10-13 | 9.60x |
| 2025-10-10 | 9.60x |
| 2025-10-09 | 9.77x |
| 2025-10-08 | 9.63x |
| 2025-10-07 | 9.56x |
| 2025-10-06 | 9.51x |
| 2025-10-03 | 9.43x |
| 2025-10-02 | 9.53x |
| 2025-10-01 | 9.34x |
| 2025-09-30 | 9.42x |
| 2025-09-29 | 9.48x |
| 2025-09-26 | 9.70x |
| 2025-09-25 | 9.87x |
| 2025-09-24 | 9.97x |
| 2025-09-23 | 9.99x |
| 2025-09-22 | 10.21x |
| 2025-09-19 | 10.08x |
| 2025-09-18 | 10.16x |
| 2025-09-17 | 9.83x |
| 2025-09-16 | 10.12x |
| 2025-09-15 | 10.37x |
| 2025-09-12 | 10.41x |
| 2025-09-11 | 10.30x |
| 2025-09-10 | 10.29x |
| 2025-09-09 | 10.74x |
| 2025-09-08 | 10.65x |
| 2025-09-05 | 10.61x |
| 2025-09-04 | 10.55x |
| 2025-09-03 | 10.46x |
| 2025-09-02 | 10.51x |
| 2025-08-29 | 10.36x |
| 2025-08-28 | 10.29x |
| 2025-08-27 | 10.19x |
| 2025-08-26 | 10.11x |
| 2025-08-25 | 10.03x |
| 2025-08-22 | 10.08x |
| 2025-08-21 | 10.00x |
| 2025-08-20 | 10.15x |
| 2025-08-19 | 9.98x |
| 2025-08-18 | 9.85x |
| 2025-08-15 | 9.80x |
| 2025-08-14 | 9.63x |
| 2025-08-13 | 9.42x |
| 2025-08-12 | 9.45x |
| 2025-08-11 | 9.31x |
| 2025-08-08 | 9.37x |
| 2025-08-07 | 9.27x |
| 2025-08-06 | 9.53x |
| 2025-08-05 | 9.66x |
| 2025-08-04 | 9.89x |
| 2025-08-01 | 9.79x |
| 2025-07-31 | 9.91x |
| 2025-07-30 | 10.24x |
| 2025-07-29 | 10.01x |
| 2025-07-28 | 10.04x |
| 2025-07-25 | 9.97x |
| 2025-07-24 | 9.85x |
| 2025-07-23 | 9.85x |
| 2025-07-22 | 9.81x |
| 2025-07-21 | 9.66x |
| 2025-07-18 | 9.77x |
| 2025-07-17 | 9.74x |
| 2025-07-16 | 9.90x |
| 2025-07-15 | 9.96x |
| 2025-07-14 | 10.03x |
| 2025-07-11 | 9.94x |
| 2025-07-10 | 10.21x |
| 2025-07-09 | 10.21x |
| 2025-07-08 | 10.18x |
| 2025-07-07 | 10.32x |
| 2025-07-03 | 10.33x |
| 2025-07-02 | 10.35x |
| 2025-07-01 | 10.30x |
| 2025-06-30 | 10.78x |
| 2025-06-27 | 10.74x |
| 2025-06-26 | 10.63x |
| 2025-06-25 | 10.51x |
| 2025-06-24 | 10.67x |
| 2025-06-23 | 10.56x |
| 2025-06-20 | 10.40x |
| 2025-06-18 | 10.36x |
| 2025-06-17 | 10.45x |
| 2025-06-16 | 10.52x |
| 2025-06-13 | 10.45x |
| 2025-06-12 | 10.42x |
| 2025-06-11 | 10.37x |
Showing the most recent 260 of 4,808 data points. The chart above shows the full history.
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy